[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:solid-neoplasm:hla-class-i-histocompatibility-antigen-a-0201-alpha-chain":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Solid Neoplasm","HLA Class I Histocompatibility Antigen, A-0201 Alpha Chain",7,[8,16,22,29,35,41,48],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05338658","Study of PAT in Patients With Solid Tumor Cancers",[12],"Phase 1","RECRUITING","2026-08-26T02:17:22.153941Z","2026-05-05T02:43:27.915457Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06402201","First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors",[12],"2026-08-26T02:17:30.145302Z","2026-04-29T02:57:57.159591Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT03686124","ACTengine® IMA203\u002FIMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and\u002For Refractory Solid Tumors",[26],"Phase 1\u002FPhase 2","2026-08-26T02:16:58.658552Z","2026-05-05T02:43:29.324355Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT05483491","KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer",[12],"2026-08-26T02:19:25.538428Z","2026-07-05T05:32:16.806172Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06778863","A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation",[12],"2026-08-26T02:15:47.754948Z","2026-05-05T02:43:26.672516Z",{"nct_id":42,"title":43,"phases":44,"status":45,"updated_at":46,"content_modified":47},"NCT07389239","A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.",[26],"NOT_YET_RECRUITING","2026-08-26T02:19:15.498463Z","2026-05-05T02:43:29.075289Z",{"nct_id":49,"title":50,"phases":51,"status":45,"updated_at":52,"content_modified":53},"NCT06748872","EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And\u002For Synovial Sarcoma",[12],"2026-08-26T02:15:03.757872Z","2026-05-05T02:43:28.536530Z"]